Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative

Objective The rational combination of immunotherapy with standard chemotherapy shows synergistic clinical activities in cancer treatment. In the present study, an oral powder formulation of pemetrexed (PMX) was developed to enhance intestinal membrane permeability and investigate its application in metronomic chemotherapy in combination with immunotherapy. Methods PMX was ionically complexed with a bile acid derivative (Nα-deoxycholyl-l-lysyl-methylester; DCK) as a permeation enhancer and mixed with dispersing agents, such as poloxamer 188 (P188) and Labrasol, to form an amorphous oral powder formulation of PMX/DCK (PMX/DCK-OP). Results The apparent permeability (Papp) of PMX/DCK-OP across a Caco-2 cell monolayer was 2.46- and 8.26-fold greater than that of PMX/DCK and free PMX, respectively, which may have been due to the specific interaction of DCK with bile acid transporters, as well as the alteration of membrane fluidity due to Labrasol and P188. Furthermore, inhibition of bile acid transporters by actinomycin D in Caco-2 cell monolayers decreased the Papp of PMX/DCK-OP by 75.4%, suggesting a predominant role of bile acid transporters in the intestinal absorption of PMX/DCK-OP. In addition, caveola/lipid raft-dependent endocytosis, macropinocytosis, passive diffusion, and paracellular transport mechanisms significantly influenced the permeation of PMX/DCK-OP through the intestinal membrane. Therefore, the oral bioavailability of PMX/DCK-OP in rats was 19.8%±6.93%, which was 294% higher than that of oral PMX. Moreover, an in vivo anticancer efficacy study in B16F10 cell-bearing mice treated with a combination of oral PMX/DCK-OP and intraperitoneal anti-PD1 exhibited significant suppression of tumor growth, and the tumor volume was maximally inhibited by 2.03- and 3.16-fold compared to the oral PMX/DCK-OP and control groups, respectively. Conclusion These findings indicated the therapeutic potential of a combination of low-dose oral chemotherapy and immunotherapy for synergistic anticancer efficacy.

[1]  N. Pavlović,et al.  Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles , 2018, Front. Pharmacol..

[2]  Y. Byun,et al.  Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect , 2018, International journal of nanomedicine.

[3]  Bo Zhang,et al.  The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2018, BioMed research international.

[4]  Yao Jin,et al.  Improved intestinal absorption of paclitaxel by mixed micelles self-assembled from vitamin E succinate-based amphiphilic polymers and their transcellular transport mechanism and intracellular trafficking routes , 2018, Drug delivery.

[5]  Zhipeng Chen,et al.  Improving intestinal absorption and oral bioavailability of curcumin via taurocholic acid-modified nanostructured lipid carriers , 2017, International journal of nanomedicine.

[6]  B. Sarmento,et al.  Strategies for the enhanced intracellular delivery of nanomaterials , 2017, Drug Discovery Today.

[7]  Yu-Li Chen,et al.  Metronomic chemotherapy and immunotherapy in cancer treatment. , 2017, Cancer letters.

[8]  S. Heilshorn,et al.  Improvement of paracellular transport in the Caco-2 drug screening model using protein-engineered substrates. , 2017, Biomaterials.

[9]  Vivek S. Dave,et al.  Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules , 2017, Drug Development and Industrial Pharmacy.

[10]  L. Sequist,et al.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.

[11]  Y. Byun,et al.  Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  E. Moghimipour,et al.  Absorption-Enhancing Effects of Bile Salts , 2015, Molecules.

[13]  Eun Seong Lee,et al.  Multifunctional Delivery Systems for Advanced oral Uptake of Peptide/Protein Drugs. , 2015, Current pharmaceutical design.

[14]  P. Dawson,et al.  Intestinal transport and metabolism of bile acids , 2015, Journal of Lipid Research.

[15]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[16]  N. Sanders,et al.  Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[17]  R. Holma,et al.  Deoxycholic acid induced changes in electrophysiological parameters and macromolecular permeability in murine small intestine with and without functional enteric nervous system plexuses , 2014, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[18]  G. Francia,et al.  Metronomic chemotherapy , 2014, Springer Berlin Heidelberg.

[19]  Shweta Gupta,et al.  Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems , 2013, ISRN pharmaceutics.

[20]  Rahul P Gangwal,et al.  Oral delivery of anticancer drugs: challenges and opportunities. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Qiang Zhang,et al.  The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. , 2013, Biomaterials.

[22]  K. Wasan,et al.  Dose-Dependent Targeted Suppression of P-glycoprotein Expression and Function in Caco-2 Cells , 2013, Molecular pharmaceutics.

[23]  W. Kaiser,et al.  The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels , 2013, International journal of nanomedicine.

[24]  Y. Byun,et al.  Oral Delivery of Ionic Complex of Ceftriaxone with Bile Acid Derivative in Non-human Primates , 2013, Pharmaceutical Research.

[25]  M. Brandl,et al.  Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188 , 2012, The Journal of pharmacy and pharmacology.

[26]  F. Hu,et al.  Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation , 2012, International journal of nanomedicine.

[27]  B. Aungst.  Absorption Enhancers: Applications and Advances , 2012, The AAPS Journal.

[28]  C. Burd,et al.  Physiology and Pathology of Endosome‐to‐Golgi Retrograde Sorting , 2011, Traffic.

[29]  M. A. Mirza,et al.  Oral lipid based drug delivery system (LBDDS): formulation, characterization and application: a review. , 2011, Current drug delivery.

[30]  Amit Kumar,et al.  Unveiling the mechanism of uptake and sub-cellular distribution of cerium oxide nanoparticles. , 2010, Molecular bioSystems.

[31]  Y. Chiang,et al.  Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Sushama Talegaonkar,et al.  Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. , 2009, Drug discovery today.

[33]  C. Herrenknecht,et al.  Development and validation of an improved liquid chromatography-mass spectrometry method for the determination of pemetrexed in human plasma. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[34]  R. Teasdale,et al.  Defining Macropinocytosis , 2009, Traffic.

[35]  Gaurav Sahay,et al.  Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. , 2008, Bioconjugate chemistry.

[36]  C. Apicella,et al.  Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[37]  Bong Kyu Yoo,et al.  Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. , 2007, International journal of pharmaceutics.

[38]  J. Polli,et al.  Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. , 2006, Molecular pharmaceutics.

[39]  J. Polli,et al.  Increased acyclovir oral bioavailability via a bile acid conjugate. , 2004, Molecular pharmaceutics.

[40]  R. Neubert,et al.  In‐vitro and in‐vivo studies of cefpirom using bile salts as absorption enhancers , 2003, The Journal of pharmacy and pharmacology.

[41]  Kanji Takada,et al.  Enhanced intestinal absorption of vancomycin with Labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats. , 2003, International journal of pharmaceutics.

[42]  M. G. Rimoli,et al.  Glycosyl Derivatives of Dopamine and l-dopa as Anti-Parkinson Prodrugs: Synthesis, Pharmacological Activity and In Vitro Stability Studies , 2003, Journal of drug targeting.

[43]  Ronald T. Borchardt,et al.  Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa? , 2002, Pharmaceutical Research.

[44]  P. Paoletti,et al.  Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. , 2001, The oncologist.

[45]  B. Shneider.  Intestinal bile acid transport: biology, physiology, and pathophysiology. , 2001, Journal of pediatric gastroenterology and nutrition.

[46]  M. Khan,et al.  Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. , 2001, International journal of pharmaceutics.

[47]  V. Hruby,et al.  Enkephalin glycopeptide analogues produce analgesia with reduced dependence liability. , 2000, Journal of medicinal chemistry.

[48]  Suzanne F. Jones,et al.  A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation , 1999, Cancer Chemotherapy and Pharmacology.

[49]  P. Swaan.  Recent Advances in Intestinal Macromolecular Drug Delivery via Receptor-Mediated Transport Pathways , 1998, Pharmaceutical Research.

[50]  P. Orlandi,et al.  Filipin-dependent Inhibition of Cholera Toxin: Evidence for Toxin Internalization and Activation through Caveolae-like Domains , 1998, The Journal of cell biology.

[51]  T. Ono,et al.  Regulation of expression of human intestinal bile acid-binding protein in Caco-2 cells. , 1998, The Biochemical journal.

[52]  Peter Oelkers,et al.  Bile acid transporters , 1995, Current opinion in lipidology.

[53]  J. Lippincott-Schwartz,et al.  Brefeldin A: insights into the control of membrane traffic and organelle structure , 1992, The Journal of cell biology.

[54]  F. Guengerich.  Characterization of human cytochrome P450 enzymes , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  P. Artursson,et al.  Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicities across monolayers of intestinal epithelial (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.

[56]  Ronald T. Borchardt,et al.  Are MDCK Cells Transfected with the Human MRP2 Gene a Good Model of the Human Intestinal Mucosa? , 2004, Pharmaceutical Research.

[57]  J. Schellens,et al.  Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093) , 2004, Cancer Chemotherapy and Pharmacology.

[58]  J. Dressman,et al.  Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration , 2004, Pharmaceutical Research.

[59]  S. Hubbard,et al.  Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.

[60]  Y. Kawashima,et al.  International Journal of Nanomedicine Dovepress Hydrophobic Ion Pairing of an Insulin-sodium Deoxycholate Complex for Oral Delivery of Insulin , 2022 .